Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Switching on kinases: oncogenic activation of BRAF and the PDGFR family.

Nature reviews. Cancer - 1 Sept 2004

Dibb Nick J, Dilworth Stephen M, Mol Clifford D

Abstract excerpt

The cytoplasmic serine/threonine kinase BRAF and receptor tyrosine kinases of the platelet-derived growth factor receptor (PDGFR) family are frequently activated in cancer by mutations of an equivalent amino acid. Structural studies have provided important insights into why these very different kinases share similar oncogenic hot spots and why the PDGFR juxtamembrane region is also a frequent oncogenic target....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Transformation, Neoplastic
Share to Enzyme Inhibitors
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Oncogenes

Share to Phosphotransferases

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-raf

Share to Receptors, Platelet-Derived Growth Factor

Source

Identifiers

PMID: 15343278
DOI: 10.1038/nrc1434

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Switching on kinases: oncogenic activation of BRAF and the PDGFR family.PMID 15343278Read ↗

PDGFRA K385 mutants in myxoid glioneuronal tumors promote receptor dimerization and oncogenic signaling.Semantic proximity Read ↗

Autophosphorylation on S614 inhibits the activity and the transforming potential of BRAF.Semantic proximity Read ↗

Oncogenic derivatives of platelet-derived growth factor receptors.Semantic proximity Read ↗

Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapiesSemantic proximity Read ↗

Computational analysis revealing that K634 and T681 mutations modulate the 3D-structure of PDGFR-β and lead to sunitinib resistanceSemantic proximity Read ↗

Mutations That Confer Drug-Resistance, Oncogenicity and Intrinsic Activity on the ERK MAP Kinases-Current State of the Art.Semantic proximity Read ↗

PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutationsSemantic proximity Read ↗

A conserved arginine within the αC-helix of Erk1/2 is a latch of autoactivation and of oncogenic capabilities.Semantic proximity Read ↗

Activating Mutations Cluster in the “Molecular Brake” Regions of Protein Kinases and Do Not Associate with Conserved or Catalytic ResiduesSemantic proximity Read ↗

Function and evolution of B-Raf loop dynamics relevant to cancer recurrence under drug inhibition.Semantic proximity Read ↗

Differential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communication.Semantic proximity Read ↗

A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.